Astrazeneca: applies for approval of lynparza In the EU
(CercleFinance.com) - The CHMP recommends approval of lynparza in the EU for castration-resistant metastatic prostate cancer mutated by BRCA.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has based its positive opinion on a subgroup analysis of patients with BRCA1/2 mutations from the PROfound Phase III trial.
Prostate cancer is the second most common type of cancer for men.
José Baselga, Executive Vice President, Oncology R&D, said, "Patients diagnosed with metastatic castration-resistant prostate cancer unfortunately have few treatment options and historically a poor prognosis. This recommendation for Lynparza brings us closer to making the only PARP inhibitor to improve overall survival in this setting available to men in the EU".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has based its positive opinion on a subgroup analysis of patients with BRCA1/2 mutations from the PROfound Phase III trial.
Prostate cancer is the second most common type of cancer for men.
José Baselga, Executive Vice President, Oncology R&D, said, "Patients diagnosed with metastatic castration-resistant prostate cancer unfortunately have few treatment options and historically a poor prognosis. This recommendation for Lynparza brings us closer to making the only PARP inhibitor to improve overall survival in this setting available to men in the EU".
Copyright (c) 2020 CercleFinance.com. All rights reserved.